explore -WSS

explore

author：hotspot 2025-09-06 04:50:58 - browse：2127

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： What causes an itch? Researchers may have solved the mystery

focus

WSS

Johnson & Johnson sues to stop Medicare negotiation

Why sickle cell disease is getting the first CRISPR treatment

A Theranos scientist

Robert Kennedy Jr.'s presidential campaign attracts GOP

What causes an itch? Researchers may have solved the mystery

A look at other Americans who have crossed into North Korea over the years

Wikipedia

explore

Gilead needs Arcellx more than ever

explore

What does generative AI mean for health care? We asked experts

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

State Dept. review finds Biden bears some blame for Afghanistan failures

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

As demand for Covid shots wanes, Moderna seeks its next success

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Medicare details structure of new drug price negotiation program

Twill hunts for pharma partner to market its depression app

As demand for Covid shots wanes, Moderna seeks its next success

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

hotspot

What causes an itch? Researchers may have solved the mystery

Twill hunts for pharma partner to market its depression app

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Why you get paid to donate plasma but not blood

Flagship, Pfizer team up in deal worth up to $7 billion

SCOTUS to consider access to abortion pill mifepristone

Wikipedia

focus

focus

leisure time